## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subjording Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	ect to
---	--------

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

1. Name and Addres ACKERMAN	1 0	n*	2. Issuer Name and Ticker or Trading Symbol <u>CHARLES RIVER LABORATORIES</u> <u>INTERNATIONAL INC</u> [ CRL ]		tionship of Reporting Persor all applicable) Director Officer (give title below)	(s) to Issuer 10% Owner Other (specify below)
(Last) 251 BALLARDY	(First) /ALE STREET	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 08/11/2008		Corp. Executive VP	,
(Street) WILMINGTON	MA (State)	01887 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	idual or Joint/Group Filing (( Form filed by One Reporti Form filed by More than C Person	ing Person

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)	ction Instr.	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Stock	08/11/2008		F		1,164	D	\$66.05	73,438	D		
Common Stock	08/11/2008		М		7,500	A	\$31.97	80,938	D		
Common Stock	08/11/2008		<b>S</b> <sup>(1)</sup>		450	D	\$66	80,488	D		
Common Stock	08/11/2008		<b>S</b> <sup>(1)</sup>		800	D	\$66.2502	79,688	D		
Common Stock	08/11/2008		<b>S</b> <sup>(1)</sup>		600	D	\$66.26	79,088	D		
Common Stock	08/11/2008		<b>S</b> <sup>(1)</sup>		100	D	\$66.2675	78,988	D		
Common Stock	08/11/2008		<b>S</b> <sup>(1)</sup>		200	D	\$66.31	78,788	D		
Common Stock	08/11/2008		<b>S</b> <sup>(1)</sup>		183	D	\$66.3102	78,605	D		
Common Stock	08/11/2008		<b>S</b> <sup>(1)</sup>		367	D	\$66.35	78,238	D		
Common Stock	08/11/2008		<b>S</b> <sup>(1)</sup>		750	D	\$66.4	77,488	D		
Common Stock	08/11/2008		<b>S</b> <sup>(1)</sup>		1,000	D	\$65.7	76,488	D		
Common Stock	08/11/2008		<b>S</b> <sup>(1)</sup>		450	D	\$65.96	76,038	D		
Common Stock	08/11/2008		<b>S</b> <sup>(1)</sup>		100	D	\$65.98	75,938	D		
Common Stock	08/11/2008		<b>S</b> <sup>(1)</sup>		500	D	\$66.12	75,438	D		
Common Stock	08/11/2008		<b>S</b> <sup>(1)</sup>		250	D	\$66.125	75,188	D		
Common Stock	08/11/2008		<b>S</b> <sup>(1)</sup>		250	D	\$66.28	74,938	D		
Common Stock	08/11/2008		<b>S</b> <sup>(1)</sup>		500	D	\$66.2802	74,438	D		
Common Stock	08/11/2008		<b>S</b> <sup>(1)</sup>		1,000	D	\$65.7	73,438	D		

 
 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code (	ransaction of ode (Instr. Derivative		nsaction de (Instr. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock Options (Right to Buy)	\$31.97	08/11/2008		М			7,500	08/01/2002	08/01/2011	Common Stock	7,500	\$0.00	2,757	D			

Explanation of Responses:

1. This sale occured pursuant to a 10b5-1 Trading Plan.

<u>/s/Thomas F Ackerman</u>

\*\* Signature of Reporting Person

08/12/2008

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY SECTION 16 FILINGS

Know all by these presents, that the undersigned hereby constitutes and appoints Joanne (Jody) P. Acford and Matthew L. Daniel as the undersigned's true and lawful attorneys in fact to:

(1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the SEC) a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC;

(2) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Charles River Laboratories International, Inc. (the Company), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder, and any other forms or reports the undersigned may be required to file in connection with the undersigned's ownership, acquisition, or disposition of securities of the Company;

(3) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney in fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney in fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney in fact may approve in such attorney in fact's discretion.

The undersigned hereby grants the attorney in fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney in fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney in fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys in fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 8th day of February, 2008.

/s/Thomas F. Ackerman

Signature